IMGN853 linked to improved outcomes in (FRα)-high platinum-resistant ovarian cancer

NYU pain research center receives $4.5M NIH grant to study chemotherapy-related pain

NIH has awarded a five-year, $4.63 million grant to NYU College of Dentistry researchers to study chemotherapy-induced painful peripheral neuropathy, or CIPPN.

October 11, 2024

Vol.50 No.38

In Brief

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

Scientists at the University of Oxford are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 (approximately US$800,000) for the study over the next three years to support lab research into the vaccine.

October 04, 2024

Vol.50 No.37

Drugs & Targets

EC approves Vyloy + chemo for advanced gastric and GEJ cancers

The European Commission approved Vyloy (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic human epidermal growth factor receptor 2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are claudin 18.2 positive.

September 27, 2024

Vol.50 No.36

Clinical Roundup

Data from phase I/II study shows Rina-S improves ORR for treatment of ovarian cancer

Data from the phase I/II study of Rina-S (rinatabart sesutecan), an investigational folate receptor-alpha-targeted, Topo1 antibody-drug conjugate, demonstrated a confirmed objective response rate of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every three weeks, regardless of FRα expression levels.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Incyte’s CDK2 inhibitor shows evidence of clinical activity in treating advanced solid tumors, notably ovarian cancer

Incyte announced early clinical data for INCB123667, a highly selective CDK2 inhibitor, in patients with advanced solid tumors.

September 20, 2024

Vol.50 No.35

Clinical Roundup

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.

September 06, 2024

Vol.50 No.33

IMGN853 linked to improved outcomes in (FRα)-high platinum-resistant ovarian cancer

YOU MAY BE INTERESTED IN

NYU pain research center receives $4.5M NIH grant to study chemotherapy-related pain

Oxford team receives $800K from CRUK to create vaccine for ovarian cancer

EC approves Vyloy + chemo for advanced gastric and GEJ cancers

Data from phase I/II study shows Rina-S improves ORR for treatment of ovarian cancer

Incyte’s CDK2 inhibitor shows evidence of clinical activity in treating advanced solid tumors, notably ovarian cancer

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login